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The experimental immunosuppressive drug FK 506 was given to 36 renal 
transplant recipients, many of whom were highly sensitized. Ten were undergo-
ing kidney retransplantation, 10 also underwent liver transplantation at an earlier 
time (6 patients) or concomitantly (4 patients), and 2 patients received a third 
organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 
13 months, all but 2 of the 36 patients are alive, 29 (81 %) are dialysis 'free, and 
most have good renal function. Twenty of the 29 dialysis-free patients are 
receiving no or low-dose (2.5 to 5.0 mg/d) prednisone therapy. Only one kidney 
was lost to cellular rejection. However, patients who had antidonor cytotoxic 
antibodies in current or historical serum samples had a high rate (3 of 9) of 
irreversible humoral rejection. A low incidence of posttransplant hypertension 
was noteworthy. Hirsutism and gingival hyperplasia were not observed. Serum 
cholesterol levels in patients who took FK 506 were unexpectedly low, and the 
effect on the level of uric acid was minimal. The side effects of FK 506 therapy 
include nephrotoxicity, neurotoxicity, and potential induction of a diabetic state. 
These are similar to the side effects of cyclosporine use, but probably less 
severe. The seeming safety, efficacy, and relative freedom from side effects of 
FK 506 encourage further trials in kidney transplantation. 
ENCOURAGING clinical trials in liver 
transplantation have been reported 
with the new immunosuppressive agent 
FK 506, j·3 which is produced by the fun-
gus Streptomyces tsukubaensis. 4,5 Al-
though the molecular structure of FK 
506 is unrelated to cyclosporine and has 
a different cytosolic binding site,6,7 the 
two drugs have similar effects on the 
immune system. 8,9 We report here a trial 
ofFK 506 in kidney recipients, of whom 
the majority had complex clinical prob-
lems or were at high risk because of 
adverse medical or immunologic 
factors. 
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METHODS 
ReCipient Case Material 
Complexity factors in the 36 patients 
included concomitant or prior liver 
transplantation (29%), previous kidney 
transplantation (29%), and causes ofre-
nal failure that increase the risk of 
transplantation (Table 1). The only child 
in the series (10 years old) had hemolytic 
uremic syndrome. Hemolytic uremic 
syndrome is a known complication of 
cyclosporine uselO that has been treated 
successfully with FK 506." Five pa-
tients were older than 60 years. 
Donor Features 
Cadaveric kidneys were used in 34 
recipients, with son-to-mother and fa-
ther-to-daughter donation in the other 
2. Five of the cadaver donors were 57 to 
64 years old, and 8 infants who were 4 to 
26 months old donated en bloc kidneys. 
The cold ischemia time for the cadaveric 
grafts was 32 ± 10 (SD) hours. Twenty-
eight (82%) of34 cadaveric grafts as well 
as the 2 living donor grafts had primary 
function as defined by early diuresis and 
freedom of the recipient from dialysis 
for the first postoperative week. 
Immunologic Matching 
There were no good HLA matches 
(defined as four or more antigen match-
es), and multiple mismatches were 
present (Table 2). Almost one third of 
the recipients had cytotoxic antibodies 
(Table 3). In 9 of 36 patients, the trans-
plantation was carried out despite a pos-
itive ( + ) or equivocally positive ( ±) cy-
totoxic crossmatch (Table 4) after the 
dithiothreital treatment of stored or 
current recipient serum, which re-
moves IgM antibodies that can cause 
false-positive crossmatches. 12 Trans-
plantation under these circumstances is 
dangerous13 1,; but has been justified in 
highly sensitized patients whose wait 
for a kidney otherwise can be end-
less. 16,17 
Immunosuppression 
A 4-hour intravenous infusion of 
0.075 mg/kg of FK 506 is given every 
12 hours until starting oral doses of 
0.15 mg/kg twice daily. Oral doses were 
increased when indicated by suspected 
rejection or reduced in size or frequency 
if a toxic reaction to a drug was sus-
pected. Plasma concentrations of FK 
506 were measured once or twice a week 
by the two-step monoclonal enzyme im-
munoassay technique of Tamura et al. 18 
Prednisone therapy was started at 
200 mg on the first postoperative day 
and reduced in daily 40-mg steps to a 
daily maintenance dose of 20 mg by day 
6. Further reductions were made quick-
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Table 1. -Clinical Features of 36 Kidney Recipients (March 27, 1989, to January 3, 1990)* 
No. of 
Organs 
No. of 
Recipients 
Complexity Factors 
Primary kidney transplant only 
Previous kidney transplant 
Patients 
Kidneys 
Previous liver transplant 
Patients 
Livers 
Simultaneous liver transplant 
Liver only 
Liver-pancreas 
Liver-heart 
Total 
16 
10 
12 
6 
9 
4 
2 
36 
Causes of Renal Failure 
Glomerulonephritis 8 
Cyclosporine toxicity 7 
Diabetes mellitus 7 
Chronic renal rejection and cyclosporine toxicity 4 
Hypertension 3 
Polycystic disease 2 
Hemolytic uremia syndrome 2 
Focal glomerulosclerosis 
Lupus nephritis 
Sickle-cell disease 
Total 36 
*Age, 40 ± 14.4 (SD) years; range, 10 to 67 years. Sixteen patients were men and 20 were women. Transplantation 
dates are shown in Table 5. 
Table 2.-HLA Antigen Matches and Mismatches 
in 34 Patients· 
No. (%) o! Patients 
Antigen No. Matches Mismatches 
6 o (0) 5 (14.7) 
5 o (0) 7 (20.9) 
4 o (0) 13 (38.2) 
3 4 (11.8) 8 (23.5) 
2 11 (32.3) 1 (2.9) 
1 10 (29.4) o (0) 
0 9 (26.5) o (0) 
Total 34 (100) 34 (100) 
*Incomplete data for two other patients. 
Table 3.-Panel Reactive Antibody (PRA) With 
Testing Against Lymphocytes of 62 Volunteers 
No. (%J of yolunteers 
%PRA Historical Current 
40-100 7 (19.4) 4 (11.1) 
10-36 4 (11.1) 7 (19.4) 
0-9 25 (69.4) 25 (69.4) 
Total 36 36 
Table 4.-Cytotoxic Crossmatch After Treating Re-
cipient Serum With Dithiothreital"* 
Historical Current No. (%) of 
Serum Serum Cases 
+ 2 (5.6) 
± 4 (11.1) 
+/ci.. .i. 3 (8.3) 
27 (75.0) 
*+indicates 20% to 40% killing; ±, 10% to 20% 
killing; and -, less than 10% killing. 
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ly if renal function was adequate. One-
gram boluses of hydrocortisone or 
methylprednisolone were given ifrejec-
tion supervened, and a 3- to 7-day 
course of 5 or 10 mg/d of OKT319 was 
given intravenously if rejection per-
sisted. Performance of a kidney biopsy 
in 17 of 36 patients reflected dissatisfac-
tion with the clinical course and uncer-
tainty about the diagnosis. 
RESULTS 
Mortality 
Follow-up of surviving patients is 4 to 
13 months. There were two deaths. A 
31-year-old nondiabetic woman died of 
cardiac arrest 60 hours after receiving 
en bloc kidneys from a 6-month-old do-
nor. At autopsy, the lungs and other 
tissues were congested, and there was 
left ventricular hypertrophy. The left 
main, left arterior descending, and cir-
cumflex coronary arteries had greater 
than 90% occlusion. 
The triple-organ recipient of a cardiac 
retransplant, liver, and kidney (patient 
29) had rapid recurrence of the hepatitis 
that had destroyed her native liver. She 
died after 4 months of liver failure; be-
cause there was no response to interfer-
on alfa therapy, a family, physician, and 
patient decision was made not to at-
tempt liver retransplantation. 
Graft Losses 
Three grafts given to the nine recipi-
ents with cytotoxic antigraft antibodies 
---------_ .. _----.----- .. _------_._- ._---
had irreversible humoral rejection 
within 1 week (patients 2, 12, and 16). In 
addition, patient 25, who was an earlier 
liver recipient and who had a positive 
cytotoxic crossmatch with his subse-
quent kidney donor, had a life-threaten-
ing hemorrhage and developed two 
large intrarenal arteriovenous fistulas 
after a kidney biopsy. His serum creati-
nine level was 350 j.LmoVL. The bleeding 
was controlled and the fistulas were 
closed by radiologically controlled em-
bolization but with resulting infarction 
of two thirds of the renal graft and re-
turn to dialysis. 
Five graft losses in 27 patients with 
negative crossmatches were caused by 
death (2 patients, cited earlier), a rup-
tured mycotic aneurysm (Candida albi-
cans) of the renal artery suture line (1 
patient), rejection (1 patient), and re-
jection plus recurrent sickle-cell disease 
(1 patient). 
Graft Function 
The result in each case is given in 
Table 5. After 4 to 13 months, 27 (75%) 
of 36 patients are dialysis free. Se-
rum creatinine levels are less than 
177 j.LmoVL in 17, between 177 and 
221 j.LmoVL in 8, and more than 
221 j.Lmol/L in 2 (Table 5), Although 
graft survival is 5 (56%) of 9 when the 
cytotoxic crossmatches were equivocal-
ly or definitely positive, one of these 
kidneys was from the same donor whose 
liver was placed in the patient (case 31) a 
few hours earlier. This strategy is 
known to shield the kidney from anti-
body injury!O Two of the other 4 surviv-
ing renal grafts (cases 22 and 28) have 
imperfect function. 
Immunosuppression End Points 
Fourteen patients had a clinical rejec-
tion at some time in their course, usually 
early, and 6 with biopsy-documented 
rejection were given OKT3. The daily 
maintenance doses of FK 506 and plas-
ma FK 506 levels 2 months after trans-
plantation are shown in Table 5 for the 
27 patients who have functioning grafts. 
Twenty of these 27 patients are taking 
5 mg/d or less of prednisone, and in 16, 
steroid therapy has been stopped. 
Infections 
The recipient of a liver, second heart 
(first heart received 4 years earlier), 
and kidney had staphylococcal septice-
mia 5 days postoperatively and recru-
descence of preexisting pancreatitis. 
Her pancreas, spleen, duodenum, and 
right colon were removed on the 20th 
posttransplantation day, and all had 
patchy necrosis. She recovered from 
this procedure but died of the same 
non-A non-B hepatitis in her hepatic 
graft that destroyed her native liver. 
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Table 5.-Data on 27 Patients With Functioning Renal Grafts 
Serum Urea No. of 
Date of Creatinine Level, Nitrogen Level, Drugs for 
No. Operation Rejection JLmoliL mmol/L Hypertension 
1 * 3/27/89 Yes 115 9.6 0 
2t 4/14/89 Yes 
3* 5/21189 No 
4* 8/17/89 No 106 7.1 0 
5 9/14/89 No 176 8.6 1 
6* 10/16/89 No 71 4.6 0 
7t 10/20/89 Yes 133 22.5 0 
8 10/21/89 Yes 220 13.6 
9 10/22/89 Yes 203 11.1 0 
10 10/25/89 Yes 336 20.0 0 
11 10/25/89 No 194 12.9 
12t 10/25/89 Yes 
13 10/26/89 No 150 7.5 2 
14*:1: 11/2/89 No 106 7.9 0 
15 11/2/89 No 80 6.4 0 
16t 11/2189 Yes 
17 1119/89 No 150 10.4 0 
18 11/9/89 Yes 212 9.6 2 
19 11/10/89 Yes 
20 11/10/89 Yes 
21t 11/19/89 No 124 9.6 0 
22t 11/19/89 Yes 292 25.0 2 
23 11/19/89 No 80 9.3 
24 11/19/89 No 221 10.4 
25*t 11/26/89 Yes 
26 11126189 No 150 11.4 0 
27 11/28/89 No 80 6.4 
28*t 11/28/89 Yes 194 7.1 
29* 12/2/89 No Dead 
30 12/2/89 No Dead 
31't 12/10/89 No 80 6.8 0 
32 12/14/89 No 115 5.0 0 
33 12/14/89 No 221 11.8 0 
34* 12/16/89 No 194 10.7 2 
35 12/16/89 No 133 9.6 0 
36t 1/2/90 No 133 7.9 0 
*Also had other organs transplanted (see Table 1). 
tPositive cytotoxic crossmatch with current or historical sera. 
tPatient 14 was son to mother; patient 36 was father to daughter. All other donors were cadavers. 
§BID indicates twice daily; qd, every day. 
Two bacterial wound infections 
(drained) and two urinary tract infec-
tions were treated easily. The C albi-
cans infection that caused a renal artery 
mycotic aneurysm and graft loss in pa-
tient 3 came from the cadaver donor 
since the recipient of the other kid-
ney taking cyclosporine-azathioprine-
steroid therapy had the same complica-
tion, with a fatal outcome. Patient 4, a 
three-organ recipient, had the pancre-
atic graft removed because of an adja-
cent Candida abscess. 
Four patients with fever had cyto-
megalovirus infection diagnosed by 
buffy coat examination or gastrointesti-
nal tract endoscopic biopsy. These four 
patients (patients 3, 8, 18, and 22), who 
were among the six who were treated 
with OKT3, responded to ganciclovir 
(DHPG) therapy. No Epstein-Barr vi-
rus or adenovirus infections were seen. 
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Potential Adverse Reactions 
The ad verse reactions of FK 506 ther-
apy, which are worse with the intrave-
nous route, resembled those of cy-
closporine21·24 and included nausea, 
vomiting, and headaches. 22 Gastrointes-
tinal tract complaints were solicited in 
detail because of reports oflethal emaci-
ation in dogs. 25 Patient 24 was found to 
have a chronic duodenal ulcer 10 days 
after transplantation. Prednisone treat-
ment was stopped, with ulcer healing. 
Other than in the triple-organ recipient 
(patient 29), who had pancreatitis be-
fore transplantation, this complication 
was not seen. Liver dysfunction was not 
observed except in patients who also 
had liver transplantation. 
The frequency and severity of arteri-
al hypertension were judged by the 
need for antihypertensive medications 
(Table 5). Sixteen of 27 patients with 
FK 506 Level 
Prednisone, in Plasma, FK506, 
mgld ng/mL mglkg/d§ 
15 0.6 0.15 BID 
0 0.7 0.16 qd 
5 0.5 0.15qd 
0 0.2 0.3 
15 0.6 0.17 qd 
15 0.3 0.08 BID 
5 0.7 0.19 BID 
10 1.1 0.17 BID 
0 0.4 0.17 qd 
0 0.6 0.14BIO 
0 0.2 0.20 qd 
0 0.7 0.15 BID 
0 0.6 0.10 BID 
10 1.7 0.21 BID 
0 0.4 0.13 BID 
10 0.5 0.18 BID 
0 0.1 0.12 BID 
0 1.0 0.10BID 
0 0.4 0.10B10 
0 0.8 0.15 BID 
20 0.2 0.11 BID 
5 0.8 0.12 qd 
5 0.8 0.07 qd 
0 0.5 0.14B10 
0 0.5 0.08 BID 
0 1.2 0.13 BID 
0 1.5 0.09 BID 
functioning kidney grafts are not re-
ceiving such drugs, 7 more are taking 
one agent, and 4 patients are undergo-
ing double drug therapy. 
Neurotoxicity was limited to trem-
ors, an increased sensitivity to light, 
burning or tingling sensations that usu-
ally affected the palms of the hands or 
soles of the feet, headaches, insomnia, 
nightmares, a mood change (some bet-
ter, some worse), tinnitus (two pa-
tients), and a sensation of "racing" were 
described by variable numbers of pa-
tients when questions were asked from 
a checklist. Most of the foregoing 
symptoms were viewed by the patients 
as minor annoyances and were not re-
ported spontaneously. 
Seven of 36 patients were insulin-de-
pendent diabetics before transplanta-
tion, and an 8th was taking oral hypo-
glycemic agents. This last patient 
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(HLA-DR types 2 and 4) required insu-
lin after operation. With the institution 
of prednisone therapy, patient 7, who 
did not have the class II HLA-DR types 
3 and 4 antigen phenotypes that are as-
sociated with diabetes mellitus,26.27 be-
came insulin dependent. Patient 17, 
whose DR antigens are 3 and 6, had 
minor elevations of blood sugar levels 
before transplantation and since then 
has been treated with oral hypoglyce-
mic agents. 
Serum cholesterol concentrations of 
27 patients with functioning kidneys 
were determined from 1 to 10 months 
after transplantation. The results were 
4.6± 1.1 (SD) mmol/L (range, 2.8 to 
7.4 mmollL; normal range, 3.4 to 
6.2 mmollL, depending on age). At the 
same time, serum uric acid levels were 
416 ± 137 (SD) j.LmollL, with a range 
of 202 to 749 j.LmollL (normal, 
<506 j.LmollL for males and <416 
j.LmollL for females). 
Hirsutism and gingival hyperplasia 
were not seen. Patients who previously 
received cyclosporine reported hair 
loss. 
COMMENT 
These first trials of FK 506 therapy 
for renal transplantation were in diffi-
cult patients, with a number of recipi-
ents of other organs, an unusual repre-
sentation of older patients and those 
undergoing retransplantation, and the 
presence of several original kidney dis-
eases that impose an increased risk for 
transplantation. One fourth of the pa-
tients were presensitized with broadly 
reacting cytotoxic antibodies, and 9 had 
donor-specific cytotoxic antibodies de-
tectable in their current or stored sera. 
HLA matching was uniformly poor. Fi-
nally, 14 donors were above or below 
the usual age range of acceptability for 
organ donation. 
The effectiveness and safety of FK 
506 under these circumstances was im-
pressive. The mortality was 5.6% after 
a mean follow-up of 170 days. Three 
fourths of the kidneys are functioning 
after 4 to 13 months, for the most part 
well. This was accomplished with ad-
ministration of low doses of steroids. 
The only kidney lost to cellular rejection 
was in a patient who also had reactiva-
tion of sickle-cell disease. 
In contrast, humoral rejection de-
stroyed four grafts, three ofthese in the 
group of nine patients whose historical 
or current sera contained anti donor cy-
totoxic antibodies. The loss of one third 
of the grafts to humoral rejection in this 
subgroup as well as the suboptimal func-
tion of several of the remaining six 
grafts (inluding one lost from a renal 
biopsy accident) suggests that FK 506 
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will not permit relaxation of classical 
crossmatch criteria. 
The ability to reduce prednisone ther-
apy to a minimum or to eliminate steroid 
use altogether in more than half of the 
patients within a few postoperative 
weeks suggests that more prednisone 
than was necessary may have been giv-
en. Reserving secondary therapy for 
agents such as OKT3 and for the specific 
indication of rejection might be prefera-
ble. It was not known at the outset if 
OKT3 would be as compatible with FK 
506 as has proved to be the case in both 
our liver and kidney recipients. 
The optimal dose of FK 506 for kidney 
recipients has not yet been determined 
accurately. In liver recipients, a start-
ing maintenance oral dose of 0.15 mg/kg 
twice daily has been enough to prevent 
rejection in the majority of patients. Be-
cause oral FK 506 presumably is pre-
sented to the liver preferentially via the 
portal vein and is largely metabolized 
there,28 larger doses might be indicated 
when organs exposed only to systemic 
blood are transplanted. Consistent 
with, but not proving this hypothesis, is 
the fact that the incidence of rejection in 
the kidney patients herein reported was 
greater than that in our liver recipients. 
Even without clarification of this im-
portant matter, a randomized trial in 
more conventional kidney recipients is 
planned at the University of Pitts-
burgh. The high success rate that can be 
anticipated with either cyclosporine or 
FK 506 therapy may make comparisons 
difficult in terms solely of short-term 
patient or graft survival. Comparisons 
will then hinge on morbidity and chronic 
risk factors, of which most are identifi-
able already. These include nephrotoxi-
city, alterations of carbohydrate metab-
olism, hypertension, hypercholesterol-
emia, and neurotoxicity, which are rec-
ognized complications of cyclosporine 
use 'O as well as FK 506 therapy. From 
what has been learned so far, such side 
effects will not vitiate the value of FK 
506. 
In animals29 and humans, 'I nephrotox-
icity of FK 506 is less than that of cyclo-
sporine. When used by itself in liver 
recipients, renal function abnormalities 
in patients treated with FK 506 usually 
are relatively minor, and as in the kid-
ney recipients in this report, there has 
been a notable freedom from hyperten-
sion. If, in a randomized trial of renal 
transplantation, a crossover is at-
tempted from cyclosporine to FK 506 
therapy or vice versa, extreme caution 
will be required since FK 506 enhances 
the nephrotoxicity of cylcosporine. 1.21 It 
originally was planned to use these two 
drugs together because of their immu-
nosuppressive synergism in vitro'" and 
in animals. 30 The plan was abandoned 
after only a few clinical cases because of 
the alarming renal deterioration that 
followed. I,", 
Both cyclosporine and FK 506 influ-
ence carbohydrate metabolism by inhib-
iting insulin secretion and by increas-
ing peripheral insulin resistance. The 
changes with cyclosporine use have 
been documented extensively,1O·81-84 but 
far less is known about FK 506. The 
insulin secretion of rat and human pan-
creatic islets in culture is reduced when 
either cyclosporine or FK 506 is added 
to the medium,85,36 but the effect of FK 
506 is weaker and more quickly revers-
ible. 36 In healthy rats undergoing long-
term FK 506 therapy, there is a 10% 
increase in fasting blood sugar lev-
els without obvious histopathologic 
changes in the pancreas.37 New-onset 
diabetes has been common after renal 
transplantation and azathioprine thera-
py and has been ascribed to the concomi-
tant use of steroids. 38,89 Our belief is that 
both cyclosporine and FK 506 have dia-
betogenic qualities independent of ste-
roids. The ability to use FK 506 with no 
or low-dose steroids may reduce the ac-
tual incidence ofposttransplantation di-
abetes. Testing this hypothesis re-
quires randomized trials. 
Major neurotoxicity has not been a 
serious problem with FK 506 use, but 
the exact delineation of minor com-
plaints could be especially important for 
discriminating management. With oth-
er commonly used immunosuppressive 
agents, toxic reactions to drug use 
promptly can be detected by character-
istic changes in laboratory test results. 
Well-known examples are leukopenia 
with azathioprine therapy and deterio-
ration of renal function test results with 
cyclosporine therapy. In the absence of 
such overt system-specific toxic effects 
with FK 506, a "litmus test" or com-
plaint profile is needed to warn against 
overdose. This can be obtained by ask-
ing specific questions that the pa-
tient might otherwise consider trivial 
about headaches, sleep patterns, motor 
skills, muscle cramps, mood, and 
paresthesias. 
Because it is known that cyclosporine 
use causes hypercholesterolemia'" and 
elevations in uric acid level, 41 the unusu-
ally low serum cholesterol levels and 
normal uric acid levels in our FK 
506-trated patients are noteworthy. 
The cyclosporine-associated cosmetic 
side effects of hirsutism, gingival hy-
perplasia, and coursening of facial fea-
tures" have not been seen in our liver, 
kidney, or thoracic organ recipients, 
who now total more than 300. 
In the 1980s, the greatly improved 
immunosuppression made possible with 
FK 506-Starzl et al 
cyclosporine revolutionized the field of 
transplantation.1O FK 506 should be the 
means for further improvement and 
also for application to autoimmune dis-
eases, including those affecting the kid-
ney. Remissions of steroid-resistant ne-
phrotic syndrome from focal glomerulo-
sclerosis" and hemolytic uremic syn-
drome" already have been reported 
with FK 506 treatment. To the extent 
that such observations are verified, the 
ultimate need for kidney transplanta-
tion could be reduced. 
The study was supported by research grants 
from the Department of Veterans Affairs, Oakland 
Veterans Administration Medical Center, Pitts-
burgh, Pa, and by project grant DK 29961 from the 
National Institutes of Health, Bethesda, Md. 
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